Bayer to spend up to $4bn on Asklepios BioPharmaceutical

Germany-based Bayer will pay up to $4 billion to acquire gene therapy company Asklepios BioPharmaceutical.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Americas

Takeda, Bayer settle $173m Adynovate suit

20 May 2021 Takeda subsidiary Baxalta has agreed to drop its fightback against a $173 million award in favour of Bayer after an appeals court upheld a patent infringement win for the German conglomerate.

Big Pharma

Bayer, Apotex settle suit over cancer drug patent

13 August 2020 Bayer has settled a patent infringement suit with generics manufacturer Apotex, after claiming that its version of a cancer treatment infringed two patents.

Big Pharma

Bayer begins $240m AI drug discovery project with Exscientia

10 January 2020 Germany-based Bayer is collaborating with Exscientia, an artificial intelligence (AI)-driven drug discovery company, to accelerate the discovery of small molecule drugs focused on cardiovascular disease and oncology.

More features

Former pharma GC brings in-house perspective to McGuireWoods

Sandoz eyes US biosimilar launch as Regeneron settles

Killing the golden goose of US drug innovation: Follow the money (Part I)

Buchalter brings in new partner to head up medtech

Trump’s march-in rights threat: Why pharma is rethinking collaborations

UK gets new IP minister following cabinet reshuffle

Barnes & Thornburg reveals five new IP leaders

Former PTAB judge joins Sterne Kessler

Bayer to spend up to $4bn on Asklepios BioPharmaceutical

More on this story

Editor's picks

Editor's picks

More features